ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-01-22 08:30 |
Abivax provides 2024 strategic outlook and lays out key milestones over next 12…
|
English | 21.8 KB | ||
| 2024-01-04 08:30 |
Abivax calendrier de communication financière 2024
|
French | 93.5 KB | ||
| 2024-01-04 08:30 |
Abivax 2024 Financial Communication Calendar
|
English | 8.8 KB | ||
| 2023-12-21 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 90.5 KB | ||
| 2023-11-30 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 90.4 KB | ||
| 2023-11-21 08:30 |
Abivax annonce la reprise de son contrat de liquidité
|
French | 114.4 KB | ||
| 2023-11-21 08:30 |
Abivax announces the resumption of its liquidity contract
|
English | 9.2 KB | ||
| 2023-11-14 14:00 |
Abivax participera à la 35e « Annual Healthcare Conference » organisée par Pipe…
|
French | 131.0 KB | ||
| 2023-11-14 14:00 |
Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference
|
English | 9.2 KB | ||
| 2023-11-09 11:41 |
Franchissement de seuil
|
French | 203.9 KB | ||
| 2023-10-30 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 90.5 KB | ||
| 2023-10-27 16:15 |
Franchissement de seuils
|
French | 200.1 KB | ||
| 2023-10-27 16:14 |
Franchissement de seuils
|
French | 198.4 KB | ||
| 2023-10-24 22:05 |
Abivax annonce la réalisation de son introduction en bourse sur le Nasdaq Globa…
|
French | 149.2 KB | ||
| 2023-10-24 22:05 |
Abivax announces Closing of its Initial Public Offering on the Nasdaq Global Ma…
|
English | 11.1 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
